Updating results

571 results

Sort: Relevance | Date

Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy (TA428)

Evidence-based recommendations on pembrolizumab (Keytruda) for locally advanced or metastatic PD-L1-positive non-small-cell lung cancer (NSCLC) in adults

Technology appraisal guidance Published January 2017 Last updated September 2017

Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation (TA429)

Evidence-based recommendations on ibrutinib (Imbruvica) for treating chronic lymphocytic leukaemia in adults

Technology appraisal guidance Published January 2017

Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia (TA426)

Evidence-based recommendations on dasatinib (Sprycel), nilotinib (Tasigna) and imatinib (Glivec) for untreated chronic myeloid leukaemia in adults

Technology appraisal guidance Published December 2016

Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens (TA423)

Evidence-based recommendations on eribulin (Halaven) for treating locally advanced or metastatic breast cancer after 2 or more types of chemotherapy

Technology appraisal guidance Published December 2016

Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia (TA425)

Evidence-based recommendations on dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant/intolerant chronic myeloid leukaemia in adults

Technology appraisal guidance Published December 2016

Everolimus with exemestane for treating advanced breast cancer after endocrine therapy (TA421)

Evidence-based recommendations on everolimus (Afinitor) for treating advanced breast cancer in adults after endocrine therapy

Technology appraisal guidance Published December 2016

Ticagrelor for preventing atherothrombotic events after myocardial infarction (TA420)

Evidence-based recommendations on ticagrelor (Brilique) for preventing atherothrombotic events such as heart attacks or stroke after myocardial infarction (MI)

Technology appraisal guidance Published December 2016

Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (TA439)

Evidence-based recommendations on cetuximab (Erbitux) and panitumumab (Vectibix) for previously untreated RAS wild-type metastatic colorectal cancer in adults

Technology appraisal guidance Published March 2017 Last updated September 2017

Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor (TA415)

Evidence-based recommendations on certolizumab pegol (Cimzia) for treating severe active rheumatoid arthritis in adults who have had a tumour necrosis factor

Technology appraisal guidance Published October 2016

Apremilast for treating moderate to severe plaque psoriasis (TA419)

Evidence-based recommendations on apremilast (Otezla) for treating moderate to severe plaque psoriasis in adults

Technology appraisal guidance Published November 2016

Nivolumab for previously treated advanced renal cell carcinoma (TA417)

Evidence-based recommendations on nivolumab (Opdivo) for previously treated advanced renal cell carcinoma (RCC/kidney cancer) in adults

Technology appraisal guidance Published November 2016

Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma (TA414)

Evidence-based recommendations on cobimetinib (Cotellic) with vemurafenib (Zelboraf) for unresectable or metastatic melanoma in adults with a BRAF V600

Technology appraisal guidance Published October 2016

Elbasvir–grazoprevir for treating chronic hepatitis C (TA413)

Evidence-based recommendations on elbasvir–grazoprevir (Zepatier) for treating genotype 1 or 4 chronic hepatitis C (HCV) in adults

Technology appraisal guidance Published October 2016

Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer (TA416)

Evidence-based recommendations on osimertinib (Tagresso) for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer

Technology appraisal guidance Published October 2016

Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal) (TA436)

NICE was unable to make a recommendation about the use in the NHS of bevacizumab for epidermal growth factor receptor mutation-positive non-small-cell lung

Technology appraisal guidance Published March 2017

Ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy (terminated appraisal) (TA437)

NICE is unable to make a recommendation about the use of ibrutinib with bendamustine and rituximab for relapsed or refractory chronic lymphocytic leukaemia

Technology appraisal guidance Published March 2017

Obeticholic acid for treating primary biliary cholangitis (TA443)

Evidence-based recommendations on obeticholic acid (Ocaliva) for treating primary biliary cholangitis (CBC / cirrhosis) in adults

Technology appraisal guidance Published April 2017

Ixekizumab for treating moderate to severe plaque psoriasis (TA442)

Evidence-based recommendations on ixekizumab (Taltz) for moderate to severe plaque psoriasis in adults

Technology appraisal guidance Published April 2017

Tenofovir alafenamide for treating chronic hepatitis B (terminated appraisal) (TA435)

NICE was unable to make a recommendation about the use in the NHS of tenofovir alafenamide for treating chronic hepatitis B because no evidence submission was

Technology appraisal guidance Published March 2017

Elotuzumab for previously treated multiple myeloma (terminated appraisal) (TA434)

NICE was unable to make a recommendation about the use in the NHS of elotuzumab for previously treated multiple myeloma because no evidence submission was

Technology appraisal guidance Published March 2017

Alectinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (terminated appraisal) (TA438)

NICE is unable to make a recommendation about the use in the NHS of alectinib for anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer

Technology appraisal guidance Published March 2017

Dapagliflozin in combination therapy for treating type 2 diabetes (TA288)

Evidence-based recommendations on dapagliflozin (Forxiga) in combination therapy for treating type 2 diabetes in adults

Technology appraisal guidance Published June 2013 Last updated November 2016

Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer (terminated appraisal) (TA240)

NICE is unable to recommend the use in the NHS of panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer..

Technology appraisal guidance Published December 2011 Last updated March 2017

Pemetrexed for the maintenance treatment of non-small-cell lung cancer (TA190)

Evidence-based recommendations on pemetrexed disodium (Alimta) for the maintenance treatment of non-small-cell lung cancer (NSCLC)

Technology appraisal guidance Published June 2010 Last updated August 2017

Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA537)

Evidence-based recommendations on ixekizumab (Taltz) for treating active psoriatic arthritis after inadequate response to DMARDs in adults

Technology appraisal guidance Published August 2018

Alectinib for untreated ALK-positive advanced non-small-cell lung cancer (TA536)

Evidence-based recommendations on alectinib (Alecensa) for untreated anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer in adults

Technology appraisal guidance Published August 2018

Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine (TA535)

Evidence-based recommendations on lenvatinib (Lenvima) and sorafenib (Nexavar) for differentiated thyroid cancer in adults who have had radioactive iodine

Technology appraisal guidance Published August 2018

Dupilumab for treating moderate to severe atopic dermatitis (TA534)

Evidence-based recommendations on dupilumab (Dupixent) for treating moderate to severe atopic dermatitis in adults

Technology appraisal guidance Published August 2018

Dinutuximab beta for treating neuroblastoma (TA538)

Evidence-based recommendations on dinutuximab beta (Qarziba) for high-risk neuroblastoma in people aged 12 months and over

Technology appraisal guidance Published August 2018

Ceritinib for untreated ALK-positive non-small-cell lung cancer (TA500)

Evidence-based recommendations on ceritinib (Zykadia) for untreated anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC)

Technology appraisal guidance Published January 2018

Glecaprevir–pibrentasvir for treating chronic hepatitis C (TA499)

Evidence-based recommendations on glecaprevir–pibrentasvir (Maviret) for treating chronic hepatitis C in adults

Technology appraisal guidance Published January 2018

Lenvatinib with everolimus for previously treated advanced renal cell carcinoma (TA498)

Evidence-based recommendations on lenvatinib (Kisplyx) with everolimus for previously treated advanced renal cell carcinoma (kidney cancer) in adults

Technology appraisal guidance Published January 2018

Golimumab for treating non-radiographic axial spondyloarthritis (TA497)

Evidence-based recommendations on golimumab (Simponi) for severe non-radiographic axial spondyloarthritis in adults

Technology appraisal guidance Published January 2018

Cladribine tablets for treating relapsing–remitting multiple sclerosis (TA493)

Evidence-based recommendations on cladribine tablets (Mavenclad) for highly active relapsing–remitting multiple sclerosis (MS) in adults

Technology appraisal guidance Published December 2017

Atezolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (TA492)

Evidence-based recommendations on atezolizumab (Tecentriq) for untreated PD-L1-positive locally advanced or metastatic urothelial carcinoma in adults

Technology appraisal guidance Published December 2017 Last updated July 2018

Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA495)

Evidence-based recommendations on palbociclib (Ibrance) as initial endocrine-based therapy for hormone receptor-positive, HER2-negative, locally advanced or

Technology appraisal guidance Published December 2017

Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA496)

Evidence-based recommendations on ribociclib (Kisqali) as initial endocrine-based therapy for hormone-receptor positive, human epidermal growth factor receptor

Technology appraisal guidance Published December 2017

Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer (TA503)

Evidence-based recommendations on fulvestrant (Faslodex) for untreated locally advanced or metastatic (secondary) oestrogen-receptor positive breast cancer in

Technology appraisal guidance Published January 2018

Ibrutinib for treating relapsed or refractory mantle cell lymphoma (TA502)

Evidence-based recommendations on ibrutinib (Imbruvica) for treating relapsed or refractory mantle cell lymphoma (MCL) in adults

Technology appraisal guidance Published January 2018

Naltrexone–bupropion for managing overweight and obesity (TA494)

Evidence-based recommendations on naltrexone–bupropion (Mysimba) for managing overweight and obesity in adults

Technology appraisal guidance Published December 2017

Dapagliflozin in triple therapy for treating type 2 diabetes (TA418)

Evidence-based recommendations on dapagliflozin (Forxiga) given with 2 other drugs for treating type 2 diabetes in adults

Technology appraisal guidance Published November 2016

Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (TA422)

Evidence-based recommendations on crizotinib (Xalkori) for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer in adults

Technology appraisal guidance Published December 2016

Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer (TA424)

Evidence-based recommendations on pertuzumab (Perjeta) for HER2-positive breast cancer in adults

Technology appraisal guidance Published December 2016

Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib (TA427)

Evidence-based recommendations on pomalidomide (Imnovid) for multiple myeloma previously treated with lenalidomide and bortezomib in adults

Technology appraisal guidance Published January 2017

Mepolizumab for treating severe refractory eosinophilic asthma (TA431)

Evidence-based recommendations on mepolizumab (Nucala) for treating severe refractory eosinophilic asthma in adults

Technology appraisal guidance Published January 2017

Everolimus for advanced renal cell carcinoma after previous treatment (TA432)

Evidence-based recommendations on everolimus (Afinitor) for advanced renal cell carcinoma (kidney cancer) after previous treatment

Technology appraisal guidance Published February 2017

Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine (TA440)

Evidence-based recommendations on pegylated liposomal irinotecan (Onivyde) for treating pancreatic cancer after gemcitabine

Technology appraisal guidance Published April 2017

Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (TA525)

Evidence-based recommendations on atezolizumab (Tecentriq) for previously treated locally advanced or metastatic urothelial carcinoma in adults

Technology appraisal guidance Published June 2018

Midostaurin for untreated acute myeloid leukaemia (TA523)

Evidence-based recommendations on on midostaurin (Rydapt) for untreated FLT3-mutation-positive acute myeloid leukaemia (AML) in adults

Technology appraisal guidance Published June 2018

Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (TA522)

Evidence-based recommendations on pembrolizumab (Keytruda) for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable

Technology appraisal guidance Published June 2018 Last updated July 2018